These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27757719)

  • 1. Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family.
    Yang C; Arnold AG; Trottier M; Sonoda Y; Abu-Rustum NR; Zivanovic O; Robson ME; Stadler ZK; Walsh MF; Hyman DM; Offit K; Zhang L
    Breast Cancer Res Treat; 2016 Dec; 160(3):447-456. PubMed ID: 27757719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A synonymous germline variant PALB2 c.18G>T (p.Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers.
    Yang C; Ceyhan-Birsoy O; Mandelker D; Jairam S; Catchings A; O'Reilly EM; Walsh MF; Zhang L
    Breast Cancer Res Treat; 2019 Jan; 173(1):79-86. PubMed ID: 30255452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Characterization of an Exonic Duplication in
    Bouras A; Lafaye C; Leone M; Kherraf ZE; Martin-Denavit T; Fert-Ferrer S; Calender A; Boutry-Kryza N
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054852
    [No Abstract]   [Full Text] [Related]  

  • 4. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
    Velázquez C; Esteban-Cardeñosa EM; Lastra E; Abella LE; de la Cruz V; Lobatón CD; Durán M; Infante M
    Breast; 2019 Feb; 43():91-96. PubMed ID: 30521987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
    Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk.
    Vagena A; Papamentzelopoulou M; Kalfakakou D; Kollia P; Papadimitriou C; Psyrri A; Apostolou P; Fountzilas G; Konstantopoulou I; Yannoukakos D; Fostira F
    J Hum Genet; 2019 Aug; 64(8):767-773. PubMed ID: 31089269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.
    Concolino P; Rizza R; Hackmann K; Paris I; Minucci A; De Paolis E; Scambia G; Zuppi C; Schrock E; Capoluongo E
    Breast Cancer Res Treat; 2017 Jul; 164(2):497-503. PubMed ID: 28488140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Amin A; Loya A; Hamann U
    Breast Cancer Res Treat; 2017 Jan; 161(2):191-201. PubMed ID: 27826754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted massively parallel sequencing characterises the mutation spectrum of PALB2 in breast and ovarian cancer cases from Poland and Ukraine.
    Myszka A; Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
    Fam Cancer; 2018 Jul; 17(3):345-349. PubMed ID: 29052111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T.
    Duran-Lozano L; Montalban G; Bonache S; Moles-Fernández A; Tenés A; Castroviejo-Bermejo M; Carrasco E; López-Fernández A; Torres-Esquius S; Gadea N; Stjepanovic N; Balmaña J; Gutiérrez-Enríquez S; Diez O
    Breast Cancer Res Treat; 2019 Apr; 174(2):543-550. PubMed ID: 30552643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tandem duplication of BRCA1 exons 1-19 through DHX8 exon 2 in four families with hereditary breast and ovarian cancer syndrome.
    Du C; Mark D; Wappenschmidt B; Böckmann B; Pabst B; Chan S; Cao H; Morlot S; Scholz C; Auber B; Rhiem K; Schmutzler R; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res Treat; 2018 Dec; 172(3):561-569. PubMed ID: 30191368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and Characterization of a New BRCA2 Rearrangement in an Italian Family with Hereditary Breast and Ovarian Cancer Syndrome.
    Concolino P; Rizza R; Hackmann K; Minucci A; Scaglione GL; De Bonis M; Costella A; Zuppi C; Schrock E; Capoluongo E
    Mol Diagn Ther; 2017 Oct; 21(5):539-545. PubMed ID: 28620890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
    Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
    Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer.
    Janatova M; Kleibl Z; Stribrna J; Panczak A; Vesela K; Zimovjanova M; Kleiblova P; Dundr P; Soukupova J; Pohlreich P
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2323-32. PubMed ID: 24136930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
    Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
    Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of predicted pathogenic PALB2 variants: an analysis of mutational overlap between epithelial cancers.
    Janssen B; Bellis S; Koller T; Tischkowitz M; Liau SS
    J Hum Genet; 2020 Jan; 65(2):199-205. PubMed ID: 31619740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation.
    Pinheiro M; Peixoto A; Santos C; Escudeiro C; Bizarro S; Pinto P; Santos R; Pinto C; Guerra J; Silva J; Teixeira MR
    Cancer Genet; 2020 Oct; 248-249():18-24. PubMed ID: 32971473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report.
    Lopez-Perolio I; Leman R; Behar R; Lattimore V; Pearson JF; Castéra L; Martins A; Vaur D; Goardon N; Davy G; Garre P; García-Barberán V; Llovet P; Pérez-Segura P; Díaz-Rubio E; Caldés T; Hruska KS; Hsuan V; Wu S; Pesaran T; Karam R; Vallon-Christersson J; Borg A; ; Valenzuela-Palomo A; Velasco EA; Southey M; Vreeswijk MPG; Devilee P; Kvist A; Spurdle AB; Walker LC; Krieger S; de la Hoya M
    J Med Genet; 2019 Jul; 56(7):453-460. PubMed ID: 30890586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and Characterization of New
    Bouras A; Leone M; Bonadona V; Lebrun M; Calender A; Boutry-Kryza N
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.